Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, Neuvonen PJ.
Coadministration of gemfibrozil and itraconazole has only a minor effect on the
pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br J Clin
Pharmacol 2005;60:208–117.
Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil,
itraconazole, and their combination on the pharmacokinetics and pharmacody-
namics of repaglinide: potentially hazardous interaction between gemfibrozil and
repaglinide. Diabetologia 2003;46:347–351.
Niro R, Byers JP, Fournier RL, Bachmann K. Application of a convective-dispersion
model to predictin vivohepatic clearance fromin vitromeasurements utilizing
cryopreserved human hepatocytes. Curr Drug Metab 2003;4:357–369.
Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM.
The utility ofin vitrocytochrome P450 inhibition data in the prediction of drug–drug
interactions. J Pharmacol Exp Ther 2006;316:336–348.
Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, Tremaine LM.In vitro
cytochrome P450 inhibition data and the prediction of drug–drug interactions:
qualitative relationships, quantitative predictions, and the rank-order approach. Clin
Pharmacol Ther 2005;78:582–592.
Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P,
Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-
dependent inhibitor of CYP2 C8: implications for drug–drug interactions. Drug
Metab Dispos 2006;34:191–197.
Okey A. Enzyme induction in the cytochrome P450 system. In: Kalow W Editor.
Pharmacogenetics of Drug Metabolism. New York: Pergamon Press; 1992. p 549–608.
Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations
and St John’s wort. Lancet 2000;355:547–548.
Puga A, Maier A, Medvedovic M. The transcriptional signature of dioxin in human
hepatoma HEPG2 cells. Biochem Pharmacol 2000;60:1129–1142.
Qatanani M, Moore DD. CAR, the continuously advancing receptor, in drug
metabolism and disease. Curr Drug Metab 2005;6:329–339.
Remmel RP, Burchell B. Validation and use of cloned, expressed human drug-
metabolizing enzymes in heterologous cells for analysis of drug metabolism and
drug–drug interactions. Biochem Pharmacol 1993;46:559–566.
Roca B, Calvo B, Monferrer R. Severe rhabdomyolysis and cerivastatin-gemfibrozil
combination therapy. Ann Pharmacother 2002;36:730–731.
Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge
the gap between cDNA-expressed cytochromes P450 and native human liver
microsomes. Biochem Pharmacol 1999;57:465–480.
Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug develop-
ment:in vitrostudies and clinical consequences. Curr Drug Metab 2002;3:289–
309.
Rowland MT, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications.
Philadelphia: Lea & Febiger; 1988.
Runge-Morris M, Kocarek TA. Regulation of sulfotransferases by xenobiotic receptors.
Curr Drug Metab 2005;6:299–307.
134 METABOLISM-MEDIATED DRUG–DRUG INTERACTIONS